James Lovett has been appointed chief operating officer at Myoderm. Mr. Lovett will work with managing director Michael Cohen to lead the company’s growth and global expansion efforts.
 
“Myoderm is at a very exciting time of growth and opportunity, and I am thrilled to have James as part of the Myoderm team. We are seizing the opportunities to find new and better ways to serve our clients in our evolving industry. I believe James has the vision and expertise to help us do that in the best way for both the company and our clients,” said Mr. Cohen.
 
Mr. Lovett brings extensive leadership experience from global companies such as Covance Inc. and FMC Corp. He spent 14 years at Covance, where he led three global business units, developing and implementing growth strategies to foster business partnerships. He also held leadership roles in industry groups such as Association of Clinical Research Organizations and National Association for Biomedical Research.